Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ligand Pharma ( (LGND) ) has issued an update.
On July 2, 2025, Ligand Pharmaceuticals completed a merger between its subsidiary LNHC, Inc. and Channel Therapeutics Corporation’s subsidiary, resulting in the formation of Pelthos Therapeutics Inc. Pelthos will trade on the NYSE American exchange under the ticker symbol ‘PTHS’ and plans to launch ZELSUVMI, a novel treatment for Molluscum contagiosum infections. Ligand invested $18 million in Pelthos and will receive a 13% royalty on worldwide sales of ZELSUVMI. The merger is seen as a transformative milestone, unlocking potential for innovation and long-term value for shareholders. Pelthos also raised $50.1 million in equity capital to support the commercial launch of ZELSUVMI and other development programs.
The most recent analyst rating on (LGND) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.
Spark’s Take on LGND Stock
According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.
Ligand Pharmaceuticals scores moderately well, reflecting strong earnings call insights and positive corporate events that highlight growth potential. However, financial performance and valuation concerns temper the overall outlook. Technical indicators suggest bullish momentum but caution is advised due to overbought conditions.
To see Spark’s full report on LGND stock, click here.
More about Ligand Pharma
Ligand Pharmaceuticals is a biopharmaceutical company that supports the clinical development of high-value medicines by providing financing and licensing technologies. The company focuses on creating a diversified portfolio of biotech and pharmaceutical product revenue streams through mid- to late-stage drug development funding, royalty rights purchases, and technology licensing. Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization.
Average Trading Volume: 123,046
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.17B
Find detailed analytics on LGND stock on TipRanks’ Stock Analysis page.